Expression of the MAGE-1, -2, -3, -4, and -6 Genes in Non-Squamous Cell Carcinoma Lesions of the Head and Neck

Lee, Kang Dae; Eura, Masao; Ogi, Kojiro; Nakano, Koji; Chikamatsu, Kazuaki; Masuyama, Keisuke; Ishikawa, Takeru

doi:10.3109/00016489609137901

Cited by 16 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This discrepancy may result from different primer sets and different clinical samples. Even when molecular biological techniques considered, we have already studied the MAGE expression in other organs such as head and neck (21), lung, uterine cervix, and stomach cancers and obtained results in line with those from others (data not shown) and also verified our techniques. Further studies on the MAGE expression in colorectal carcinoma among Koreans are needed to verify the results of this study.…”

Section: Discussionsupporting

confidence: 89%

Expression of Melanoma Antigen-Encoding Genes (MAGE) by Common Primers for MAGE-A1 to -A6 in Colorectal Carcinomas Among Koreans

Park

Jeon

et al. 2002

J Korean Med Sci

Self Cite

View full text Add to dashboard Cite

This study was to investigate Melanoma-antigen gene (MAGE) expression by reverse transcription-nested polymerase chain reaction (RT-nested PCR) with the original common primers of MAGE-A1 to -A6 and analysis of correlation between its expression and the well-known clinical parameters in addition to evaluate the clinical feasibility of the common primers. Surgical tumor and corresponding nonneoplastic tissue samples from 38 patients with colorectal cancer were studied. To confirm the identities of RT-PCR products, direct sequencing was done after in vitro subcloning. No expression of MAGE was observed in the non-neoplastic colorectal mucosal tissues. Sixteen (42.1%) of 38 carcinomas expressed at least one of MAGE A-1 to -6. The expression of the MAGE genes was not related to age, sex, histological grades, the depth of invasion, metastasis to lymph nodes, vessel, neural, or perineural invasion. The identities with the corresponding mRNAs were confirmed in 6 cases for MAGE-A2 (15.8%), 6 cases for MAGE-A4 (15.8%), 2 cases for MAGE-A3 (5.3%), and one case for MAGE A-6 (2.6%). These results suggest that MAGE expressions, except those of MAGE-A2 and -A4, seem to have a limited role in the molecular pathogenesis of colon cancer. However, the common primer sets to detect of expressions for MAGE-A1 to -A6 simultaneously appear to be feasible to differentiate malignant from benign lesions in colorectal diseases.

show abstract

Section: Discussionsupporting

confidence: 89%

Expression of Melanoma Antigen-Encoding Genes (MAGE) by Common Primers for MAGE-A1 to -A6 in Colorectal Carcinomas Among Koreans

Park

Jeon

et al. 2002

J Korean Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…Diseases such as viral myocarditis, lyme disease, rheumatoid arthritis (45), multiple sclerosis (46), and virus-induced autoimmune diabetes (47,48) have long been considered to be initiated or exacerbated by microbial pathogens. As was previously noted for the HLA-A2 -presented, melanomaassociated MART-1 [27][28][29][30][31][32][33][34][35] epitope (35), we hypothesized that the high degree of normal donor response against the MAGE-A6 Th peptides might be due to the cross-reactivity of T cells initially primed in vivo against highly homologous peptides within environmentally encountered proteins. After performing a homology search of the GenBank database, we selected the MPHF2 216-229 and CHP [42][43][44][45][46][47][48][49][50][51][52][53][54][55] peptides as two likely candidate homologues of the MAGE-A6 172-187 and MAGE-A6 280-302 peptides, respectively.…”

Section: Discussionmentioning

confidence: 97%

“…An alternative possibility is that the MAGE-A6 peptides evaluated bare sufficient sequence or conformational homologies to proteins present in the environment to which many individuals may have become naturally primed against, allowing for functional cross-reactivity to be detected in our assays. This type of phenomenon has been previously suggested for the HLA-A2 -presented MART-1 [27][28][29][30][31][32][33][34][35] + Tcell responses against MAGE-A6 peptides predicted to be promiscuously presented by HLA-DR alleles and naturally processed rMAGE epitopes. CD4 + Tcells were isolated from the indicated (A) 14 melanoma patients and (B) 7 normal donors and tested for their ability to be stimulated by, and react against, the indicated MAGE-A6 peptides.…”

Section: Cd4mentioning

confidence: 92%

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

Vujanović

Mandić²,

Olson³

et al. 2007

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Although T-helper (Th) epitopes have been previously reported for many tumor antigens, including MAGE-A6, the relevant HLA-DR alleles that present these peptides are expressed by only a minority of patients. The identification of tumor antigenic epitopes presented promiscuously by many HLA-DR alleles would extend the clinical utility of these peptides in vaccines and for the immunomonitoring of cancer patients. Experimental Design: A neural network algorithm and in vitro sensitization assays were employed to screen candidate peptides for their immunogenicity. Results: The MAGE-A6 14 0 -170 , MAGE-A6 172-187 , and MAGE-A6 280-302 epitopes were recognized by CD4 + T cells isolated from the majority of normal donors and melanoma patients evaluated. Peptide-specific CD4 + T cells also recognized autologous antigen-presenting cell pulsed with recombinant MAGE-A6 (rMAGE) protein, supporting the natural processing and MHC presentation of these epitopes. Given the strong primary in vitro sensitization of normal donor CD4 + T cells by the MAGEA6 172-187 epitope, suggestive of potential cross-reactivity against an environmental stimulus, we identified a highly homologous peptide within the Mycoplasma penetrans HF-2 permease (MPHF2) protein. MPHF2 peptide^primed CD4 + Tcells cross-reacted against autologous APC pulsed with the MAGE-A6 172-187 peptide or rMAGE protein and recognized HLA-matched MAGE-A6 + melanoma cell lines. These responses seemed heteroclitic in nature because the functional avidity of MPHF2 peptide-primed CD4 + Tcells for the MAGE-A6 172-187 peptide was f1,000 times greater than that of CD4 + T cells primed with the corresponding MAGE-A6 peptide. Conclusions: We believe that these novel ''promiscuous'' MAGE-A6/MPHF2 Th epitopes may prove clinically useful in the treatment and/or monitoring of a high proportion of cancer patients.

show abstract

“…Additionally, little is known about the expression of the single antigen subgroups (MAge-A1 to -A12) in different tumour entities. Only five reported studies have investigated at least four subtypes of MAge-A antigens in wild-type oral squamous cell carcinoma (3,(12)(13)(14)(15). In light of their exclusive appearance in malignant cells and immunogenicity and their use as possible targets of immunotherapy, further investigation is warranted.…”

Section: Discussionmentioning

confidence: 99%

Impact of MAGE-A antigens on taxane response in oral squamous cell carcinoma

Müller‐Richter

Dowejko²,

Driemel³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. MAge-A antigens are a subgroup of cancer/testis antigens that are exclusively expressed in malignant cells. only scarce information on the function of MAge-A antigens is available. There is some evidence that they may influence the response to chemotherapeutic drugs. this study aimed to evaluate the impact of the MAge-A antigen subgroups MAge-A2, -A3, -A4 and -A6 on oral squamous cell carcinoma cell lines treated with docetaxel and paclitaxel. Five oral squamous cell carcinoma cell lines were characterized for their quantitative expression of MAge-A2, -A3, -A4 and -A6. the cell lines were treated with concentrations ranging from 0.025 to 0.8 µM of docetaxel and paclitaxel. the amount of viable cells after 24 and 48 h was measured. the measurements were statistically correlated with MAge-A expression. All cell lines responded to docetaxel and paclitaxel. one cell line showed a statistically significant weaker response to the taxane treatment. this cell line was the only one that expressed MAge-A4. MAGE-A4 has a statistically significant impact on the tumour response to docetaxel and paclitaxel in oral squamous cell carcinoma. This may influence treatment options and the course of the disease. therefore, patients should be evaluated for MAge-A4 expression before treatment with taxanes.

show abstract

Expression of the MAGE-1, -2, -3, -4, and -6 Genes in Non-Squamous Cell Carcinoma Lesions of the Head and Neck

Cited by 16 publications

References 18 publications

Expression of Melanoma Antigen-Encoding Genes (MAGE) by Common Primers for MAGE-A1 to -A6 in Colorectal Carcinomas Among Koreans

Expression of Melanoma Antigen-Encoding Genes (MAGE) by Common Primers for MAGE-A1 to -A6 in Colorectal Carcinomas Among Koreans

A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6

Impact of MAGE-A antigens on taxane response in oral squamous cell carcinoma

Contact Info

Product

Resources

About